Jordana Jampel

DocwireNews

A new drug that was designed using generative artificial intelligence (AI) for the treatment of inflammatory bowel disease (IBD) demonstrated a favorable pharmacokinetic (PK) profile in validating gut-restrictive properties. ISM5411, a hypoxia-inducible factor prolyl hydroxylase (PHD) inhibitor, was found to be generally safe and well tolerated in all dose groups of the phase I trials conducted in Australia and China. Study details and results were <a href="https://www.nature.com/articles/s41587-024-02503-w">published</a> in Nature Biotechnology.
The early discovery, supported by Insilico Medicine’s commercially available generative AI platform Chemistry42, of the preclinical candidate nomination of ISM5411 took only 12 months, during which approximately 115 molecules were synthesized and screened.
&#8220;It is pleased to see the good safety and PK profiles of ISM5411, especially the low systemic exposure across all dose groups. These results are suggestive of the gut-restrictive property of ISM5411 and good potential for further clinical development,&#8221; <a href="https://www.eurekalert.org/news-releases/1069644">said</a> Philip Ryan, MD, PhD, the principal investigator of ISM5411 phase I study in Australia. &#8220;As an advanced technology, AI has played important roles in drug discovery and clinical research. We are looking forward to following ISM5411 as it progresses into patient trials, where we hope to see clinical benefits stemming from this technology.&#8221;
These studies included single ascending dose (SAD), multiple ascending dose (MAD), and food effects parts involving 76 healthy participants in Australia and 48 healthy participants in China. Safety and PK data collection has been completed for both studies. There were no reports of serious adverse events or treatment-related adverse events leading to discontinuation. ISM5411 also exhibited a favorable PK profile for validating gut-restrictive properties, with very low systemic exposure and a high fecal/plasma ratio in healthy volunteers.
“Thus, we conclude that ISM012-042 is safer than existing PHD inhibitors as it exhibited low systemic inhibition of PHDs,” the researchers noted.
Source
<a href="https://www.nature.com/articles/s41587-024-02503-w">Nature Biotechnology</a>

Laura Litwin

Sublobar Resection Versus Lobectomy for Early-Stage NSCLC: Systematic Review Compares Outcomes

Non-Small Cell Lung Cancer

Emily Menendez

Sotorasib Plus Panitumumab Approved by FDA for KRAS G12C-Mutated mCRC

Colorectal Cancer

New Drug for IBD Designed Using Generative AI

Gastroenterology

Latest News

The early discovery of the preclinical candidate nomination took only 12 months. 

About Us

Editorial Policy

Advertising

eNewsletters

Contribute

Contact Us

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

Mesothelioma

Small Cell Lung Cancer

Squamous Cell Lung Carcinoma

Lung Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

The Oncology Brothers

Rheumatology Rounds With Dr. Maheswaranathan

Healthcare Unfiltered

The Fellow on Call

Partners

Hurricanes & Health Care

Career Center

Expert Interviews

Subscribe